FI50711C - Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen. - Google Patents

Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen.

Info

Publication number
FI50711C
FI50711C FI731543A FI154373A FI50711C FI 50711 C FI50711 C FI 50711C FI 731543 A FI731543 A FI 731543A FI 154373 A FI154373 A FI 154373A FI 50711 C FI50711 C FI 50711C
Authority
FI
Finland
Prior art keywords
corticosteroids
dividing
stereoisomeric mixtures
stereoisomer
components
Prior art date
Application number
FI731543A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI50711B (OSRAM
Inventor
Ralph Lennart Brattsand
Karl Goeran Claeson
Bo Thuresson Af Ekenstam
Bror Arne Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors Ab filed Critical Bofors Ab
Application granted granted Critical
Publication of FI50711B publication Critical patent/FI50711B/fi
Publication of FI50711C publication Critical patent/FI50711C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
FI731543A 1972-05-19 1973-05-14 Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen. FI50711C (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (OSRAM) 1972-05-19 1972-05-19

Publications (2)

Publication Number Publication Date
FI50711B FI50711B (OSRAM) 1976-03-01
FI50711C true FI50711C (fi) 1976-06-10

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
FI731543A FI50711C (fi) 1972-05-19 1973-05-14 Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen.

Country Status (17)

Country Link
US (1) US3928326A (OSRAM)
JP (1) JPS547794B2 (OSRAM)
BE (1) BE799728A (OSRAM)
CA (1) CA1003402A (OSRAM)
CY (1) CY1012A (OSRAM)
DE (1) DE2323216C3 (OSRAM)
DK (1) DK133249C (OSRAM)
FI (1) FI50711C (OSRAM)
FR (1) FR2185406B1 (OSRAM)
GB (1) GB1428416A (OSRAM)
HK (1) HK49079A (OSRAM)
IL (1) IL42154A (OSRAM)
KE (1) KE2969A (OSRAM)
NL (1) NL175917C (OSRAM)
SE (1) SE378110B (OSRAM)
SU (1) SU468408A3 (OSRAM)
ZA (1) ZA732956B (OSRAM)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
WO1994015947A1 (en) * 1993-01-08 1994-07-21 Astra Aktiebolag Novel colon- or ileum-specific steroid derivatives
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
WO2005100356A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2008035315A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
RU2446796C2 (ru) 2006-12-26 2012-04-10 Фармасайкликс, Инк. Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
DK2124944T3 (da) 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
UA108858C2 (xx) * 2009-09-11 2015-06-25 Похідні ізоксалідину
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
WO2011097594A2 (en) 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
DK2888255T3 (en) 2012-08-24 2018-10-29 Univ Texas HETOCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
IL307357A (en) 2016-11-08 2023-11-01 Regeneron Pharma Steroids and their protein conjugates
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
MY210236A (en) 2018-01-08 2025-09-04 Regeneron Pharma Steroids and antibody-conjugates thereof
EP3790899A1 (en) 2018-05-09 2021-03-17 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4077282A4 (en) 2019-12-17 2023-11-08 Merck Sharp & Dohme LLC Prmt5 inhibitors
PE20251401A1 (es) 2022-09-02 2025-05-22 Merck Sharp And Dohme Llc Inhibidores de topoisomerasa-1 derivados de exatecan composiciones farmaceuticas y sus usos
AU2023366166A1 (en) 2022-10-25 2025-05-01 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
EP4633681A1 (en) 2022-12-14 2025-10-22 Merck Sharp & Dohme LLC Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Also Published As

Publication number Publication date
NL175917C (nl) 1985-01-16
NL175917B (nl) 1984-08-16
NL7306979A (OSRAM) 1973-11-21
IL42154A (en) 1976-12-31
JPS547794B2 (OSRAM) 1979-04-10
CY1012A (en) 1979-11-23
DK133249B (da) 1976-04-12
DK133249C (da) 1976-09-13
KE2969A (en) 1979-07-20
DE2323216C3 (de) 1978-06-22
DE2323216A1 (de) 1973-11-29
GB1428416A (en) 1976-03-17
IL42154A0 (en) 1973-07-30
DE2323216B2 (de) 1977-11-03
FR2185406A1 (OSRAM) 1974-01-04
JPS4941379A (OSRAM) 1974-04-18
SE378110B (OSRAM) 1975-08-18
ZA732956B (en) 1974-04-24
HK49079A (en) 1979-07-27
US3928326A (en) 1975-12-23
FI50711B (OSRAM) 1976-03-01
CA1003402A (en) 1977-01-11
SU468408A3 (ru) 1975-04-25
BE799728A (fr) 1973-09-17
FR2185406B1 (OSRAM) 1976-12-31
AU5525273A (en) 1974-11-07

Similar Documents

Publication Publication Date Title
FI50711C (fi) Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen.
FI51714C (fi) Menetelmä isomaltitolin valmistamiseksi.
NL7416704A (nl) Werkwijze ter bereiding van schuimstoffen.
YU40251B (en) Process for producing oxazolidine derivatives
FI47364C (fi) Menetelmä terapeuttisesti arvokkaiden 3-indolyyli-alifaattinen-happoyh disteiden valmistamiseksi.
CH553782A (fr) Procede de preparation de nouveaux derives de pyridine.
SE7907064A0 (sv) Förfarande för framställning av naftalenderivat
FI46067C (fi) Menetelmä digitoksigeniiniglykosidien valmistamiseksi.
NL7411242A (nl) Werkwijze ter behandeling van fruit.
FI47575C (fi) Analogiamenetelmä evomonosidi-johdannaisten valmistamiseksi.
FR1394779A (fr) Procédé de nitration en continu de la cellulose
FI50407C (fi) Menetelmä trikloorimonosilaanien valmistamiseksi
FI44622C (fi) Menetelmä terapeuttisesti arvokkaiden substituoitujen naftaleenijohdan naisten valmistamiseksi.
NO741905L (no) Fremgangsmåte for styring av fremføringen av langstrakte materialstykker.
FI52735C (fi) Menetelmä uusien pregnadieeni-21-happojohdannaisten valmistamiseksi.
SE416952B (sv) Forfarande for framstellning av substituerade fenylamidinokarbamidforeningar
FI45976C (fi) Menetelmä terapeuttisesti arvokkaiden emäksisesti substituoitujen alky yliksantiinijohdannaisten valmistamiseksi.
FI49841C (fi) Menetelmä amylaasi-inhibiitin valmistamiseksi.
IT1021385B (it) Metodo per isomerizzare destrosio
NL7412404A (nl) Werkwijze ter bereiding van oleoharsemulsies.
FI46727C (fi) Menetelmä pyridatsolijohdannaisten valmistamiseksi.
FI49029C (fi) Menetelmä 15alfa,16alfa-metyleeniandrosteenijohdannaisten valmistamise ksi
FI52088C (fi) Menetelmä 3-(4-asyylioksialkyyli-1-piperatsinyyli)-karbonyylimetyyli-2 -bentsotiatsolinonijohdannaisten valmistamiseksi.
FI48347C (fi) Menetelmä 17beta-alkanoyylioksi-17alfa-propadienyyli-steroidien valmis tamiseksi.
FI50411C (fi) Menetelmä aryyliamino-2-imidatsoliinien valmistamiseksi